Fujian Boro Pharmaceutical Research Co., Ltd.

Primary objective: To compare the pharmacokinetic behavior of the test preparation crisaborole ointment (licensed by: Fujian Baonuo Pharmaceutical Research and Development Co., Ltd.) and the reference preparation crisaborole ointment (licensed by: Anacor Pharmaceuticals, Inc., trade name: Sutanming®) in healthy subjects after external application under fasting state, using pharmacokinetic parameters as the primary endpoint evaluation index, and to evaluate the bioequivalence of the two preparations. Secondary objectives: (1) To observe the safety of the test preparation crisaborole ointment and the reference preparation crisaborole ointment in healthy subjects; (2) To evaluate the skin reactivity of the test preparation crisaborole ointment and the reference preparation crisaborole ointment in healthy Chinese subjects.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation indicators, the pharmacokinetic behavior of the test preparation fenofibrate capsules (certificate holder: Fujian Baonuo Pharmaceutical Research and Development Co., Ltd.) and the reference preparation fenofibrate capsules (certificate holder: ABBOTT LABORATORIES LIMITED, trade name: Lipingzhi®) in healthy subjects after oral administration in the fasting/postprandial state was compared to evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation fenofibrate capsules and the reference preparation fenofibrate capsules in healthy subjects.

Main purpose: Paroxetine hydrochloride tablets provided by Fujian Baonuo Pharmaceutical Research and Development Co., Ltd. were used as the test preparation (T), and paroxetine hydrochloride tablets (trade name: Seroxetine®) certified by Sino-US Tianjin SmithKline Pharmaceutical Co., Ltd. were used as the reference preparation (R). The pharmacokinetic characteristics of the test preparation and the reference preparation after a single oral administration in healthy subjects in the fasting and postprandial state were evaluated, and the bioequivalence of the two preparations was evaluated. Secondary purpose: To investigate the safety of the test preparation and the reference preparation after oral administration in healthy subjects.